Permeability of the blood-brain barrier predicts no evidence of disease activity at 2 years after natalizumab or fingolimod treatment in relapsing-remitting multiple sclerosis. (2018)

First Author: Cramer SP
Attributed to:  Systemic inflammation and the blood-brain barrier in multiple sclerosis funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1002/ana.25219

PubMed Identifier: 29604233

Publication URI: http://europepmc.org/abstract/MED/29604233

Type: Journal Article/Review

Volume: 83

Parent Publication: Annals of neurology

Issue: 5

ISSN: 0364-5134